Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Moody's outlook for pharmaceutical industry as well as reports that Pfizer is looking to provide additional COVID-19 vaccine doses.
Dividend stocks aren't always known for generating sizzling gains. Here are the three best Dividend Aristocrat stocks in the first half of 2022. At its peak in early June, ExxonMobil stock was up more than 70%.
Shares of AbbVie (NYSE: ABBV) are up by about 13% this year, which is a lot better than the benchmark S&P 500 index, which has lost 20% over the same period. With lots of high-margin revenue from top-selling drugs, there's a good chance that AbbVie stock will remain a safe haven even if the U.S. economy plunges into a deep recession. The top-selling drug for AbbVie is Humira.